HK1214968A1 - 用於非酒精性脂肪肝病(nafld)的新组合物 - Google Patents

用於非酒精性脂肪肝病(nafld)的新组合物 Download PDF

Info

Publication number
HK1214968A1
HK1214968A1 HK16103017.5A HK16103017A HK1214968A1 HK 1214968 A1 HK1214968 A1 HK 1214968A1 HK 16103017 A HK16103017 A HK 16103017A HK 1214968 A1 HK1214968 A1 HK 1214968A1
Authority
HK
Hong Kong
Prior art keywords
fatty liver
nafld
liver disease
nonalcoholic fatty
novel composition
Prior art date
Application number
HK16103017.5A
Other languages
English (en)
Chinese (zh)
Inventor
Pankaj Patel
Rajendrakumar HARIPRASAD JANI
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of HK1214968A1 publication Critical patent/HK1214968A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16103017.5A 2013-04-22 2013-06-25 用於非酒精性脂肪肝病(nafld)的新组合物 HK1214968A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1468/MUM/2013 2013-04-22
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
IN1468MU2013 IN2013MU01468A (enExample) 2013-04-22 2013-06-25

Publications (1)

Publication Number Publication Date
HK1214968A1 true HK1214968A1 (zh) 2016-08-12

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103017.5A HK1214968A1 (zh) 2013-04-22 2013-06-25 用於非酒精性脂肪肝病(nafld)的新组合物

Country Status (21)

Country Link
US (3) US20160166539A1 (enExample)
EP (1) EP2988736A1 (enExample)
JP (1) JP6246895B2 (enExample)
KR (1) KR101617812B1 (enExample)
CN (1) CN105377246B (enExample)
AP (1) AP2015008674A0 (enExample)
AU (1) AU2013387996B2 (enExample)
BR (1) BR112015020600A2 (enExample)
CA (1) CA2900435C (enExample)
EA (1) EA201592020A1 (enExample)
GE (1) GEP201706663B (enExample)
HK (1) HK1214968A1 (enExample)
IL (2) IL240183A (enExample)
IN (1) IN2013MU01468A (enExample)
MA (1) MA38385A1 (enExample)
MX (1) MX346943B (enExample)
MY (1) MY180160A (enExample)
PH (1) PH12015501795A1 (enExample)
SG (1) SG11201506218UA (enExample)
UA (1) UA114360C2 (enExample)
WO (1) WO2014174524A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670486B1 (en) 2011-01-31 2016-04-06 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN109069503A (zh) * 2016-04-22 2018-12-21 景凯生物科技股份有限公司 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
TWI814744B (zh) * 2017-10-06 2023-09-11 美商基利科學股份有限公司 包含acc抑制劑之組合療法
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
KR100380875B1 (ko) 1995-04-28 2003-10-10 다이이찌 세이야꾸 가부시기가이샤 펜타사이클릭화합물
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CZ304346B6 (cs) 2000-01-19 2014-03-19 Cadila Healthcare Ltd. Substituovaný pyrrolový derivát s hypolipidemickou hypocholesteremickou aktivitou, způsob jeho přípravy a farmaceutický přípravek obsahující tyto sloučeniny
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
KR20080074101A (ko) * 2005-09-19 2008-08-12 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루카곤 수용체 발현의 조절
US7737266B2 (en) * 2006-09-18 2010-06-15 Board Of Regents, The University Of Texas System RNAi modulation of SCAP and therapeutics uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
AU2010323066B2 (en) 2009-11-26 2014-12-11 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
EP2670486B1 (en) 2011-01-31 2016-04-06 Cadila Healthcare Limited Treatment for lipodystrophy
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
KR101617812B1 (ko) 2016-05-03
MX346943B (es) 2017-04-06
US20180185330A1 (en) 2018-07-05
IN2013MU01468A (enExample) 2015-04-17
KR20150118990A (ko) 2015-10-23
US20170087127A1 (en) 2017-03-30
AP2015008674A0 (en) 2015-08-31
US20160166539A1 (en) 2016-06-16
IL240183A0 (en) 2015-09-24
IL240183A (en) 2016-08-31
UA114360C2 (uk) 2017-05-25
WO2014174524A8 (en) 2015-10-01
JP6246895B2 (ja) 2017-12-13
CA2900435C (en) 2017-02-14
BR112015020600A2 (pt) 2017-07-18
IL247231A (en) 2017-03-30
CA2900435A1 (en) 2014-10-30
MY180160A (en) 2020-11-23
GEP201706663B (en) 2017-05-10
MX2015010769A (es) 2015-11-26
EA201592020A1 (ru) 2016-05-31
AU2013387996A1 (en) 2015-09-24
CN105377246B (zh) 2018-03-20
CN105377246A (zh) 2016-03-02
EP2988736A1 (en) 2016-03-02
WO2014174524A1 (en) 2014-10-30
US9814697B2 (en) 2017-11-14
SG11201506218UA (en) 2015-09-29
MA38385A1 (fr) 2017-09-29
JP2016515608A (ja) 2016-05-30
PH12015501795A1 (en) 2015-11-09
AU2013387996B2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
MY178621A (en) Deuterated cftr potentiators
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
MX349159B (es) Derivados deuterados de ivacaftor.
NZ739248A (en) Inhibitors of hepatitis c virus
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
IN2014MN02082A (enExample)
WO2009134616A8 (en) Novel inhibitors of hepatitis c virus replication
EA201491500A1 (ru) Способы лечения фиброза
BR112016024020A2 (pt) composição farmacêutica
IN2014CN00572A (enExample)
WO2011075822A8 (en) Immunogenic compositions and related methods
MX2012012095A (es) Analogos de tiazolidinadiona.
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
BR112015022571A2 (pt) método de tratamento de esteatose hepática
NZ707773A (en) Methods of treating liver diseases
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.